ANNEXON BIOSCIENCES
Live / Registered — Registered (as of 11 Aug 2026)
What this means for you
Registered since 11 Aug 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 11 Aug 2032: the §8 declaration of use).
Record
- Serial number
- 98978455
- Registration number
- 8394643
- Mark type
- Word mark
- Filed
- 12 Aug 2024
- Published for opposition
- 18 Mar 2025
- Registered
- 11 Aug 2026
- Next maintenance filing
- §8 declaration of use, due by 11 Aug 2032 (grace period to 11 Feb 2033)
- Attorney of record
- Joshua S. Jarvis, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, and geographic atrophy
- Class 042 — Scientific and technological services: Providing medical and scientific research information in the field of pharmaceuticals and clinical trials
- Class 044 — Medical, beauty and agricultural services: Providing medical information; providing medical information related to pharmaceuticals
Owner
- Annexon, Inc., Brisbane, CA, US
- Annexon, Inc., Brisbane, CA, US
- Annexon, Inc., Brisbane, CA, US
Prosecution history
- 11 Aug 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 11 Aug 2026 — REGISTERED-PRINCIPAL REGISTER
- 20 Jul 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 20 Jul 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 13 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Jun 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 11 Sept 2025 — USE AMENDMENT FILED
- 12 Jun 2026 — SOU EXTENSION 1 GRANTED
- 10 Sept 2025 — SOU EXTENSION 1 FILED
- 12 Jun 2026 — DIVISIONAL PROCESSING COMPLETE
- 11 Sept 2025 — DIVISIONAL REQUEST RECEIVED
- 10 Jun 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Sept 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 19 Mar 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Sept 2025 — TEAS STATEMENT OF USE RECEIVED